{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591384,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2020R1I1A3074384"],"award-info":[{"award-number":["NRF-2020R1I1A3074384"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A5A2017323"],"award-info":[{"award-number":["NRF-2020R1A5A2017323"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118185","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T03:10:11Z","timestamp":1747969811000},"page":"118185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats"],"prefix":"10.1016","volume":"188","author":[{"given":"Ji-Hyeon","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1262-7110","authenticated-orcid":false,"given":"Jihoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9713-1821","authenticated-orcid":false,"given":"Yeon-Ju","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwon-Jo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Duck","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1090-6921","authenticated-orcid":false,"given":"Joon Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-5042","authenticated-orcid":false,"given":"Min-Koo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4564-709X","authenticated-orcid":false,"given":"Im-Sook","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118185_bib1","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118185_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.17406","article-title":"Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects","volume":"57","author":"Hwang","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-020-0753-y","article-title":"Novel therapies for gastroesophageal reflux disease: beyond proton pump inhibitors","volume":"22","author":"Shibli","year":"2020","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.biopha.2025.118185_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118185_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1574-6976.12027","article-title":"Survival in hostile territory: the microbiota of the stomach","volume":"37","author":"Yang","year":"2013","journal-title":"Fems. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2025.118185_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455008","article-title":"Gastric acid suppression is associated with an increased risk of adverse outcomes in in\ufb02ammatory bowel disease","volume":"95","author":"Shah","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.biopha.2025.118185_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.870817","article-title":"Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function","volume":"13","author":"Son","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118185_bib8","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41598-020-59550-x","article-title":"The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: a pilot study","volume":"10","author":"Horvath","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118185_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13841","article-title":"Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice","volume":"32","author":"Takashima","year":"2020","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.biopha.2025.118185_bib10","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1053\/j.gastro.2021.08.005","article-title":"Regular use of proton pump inhibitor and the risk of in\ufb02ammatory bowel disease: pooled analysis of 3 prospective cohorts","volume":"161","author":"Xia","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118185_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.biopha.2025.118185_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/ecp.09.33","article-title":"Long lasting inhibitors of the gastric H,K-ATPase","volume":"2","author":"Shin","year":"2009","journal-title":"Expert. Rev. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","article-title":"Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases","volume":"108","author":"Andersson","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021","volume":"57","author":"Iwakiri","year":"2022","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118185_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/pharmaceutics16060799","article-title":"In vitro metabolism and transport characteristics of zastaprazan","volume":"16","author":"Lee","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118185_bib17","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1111\/bcp.15268","article-title":"Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole","volume":"88","author":"Yang","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5009\/gnl220457","article-title":"Efficacy and safety of fexuprazan in patients with acute or chronic gastritis","volume":"17","author":"Kim","year":"2023","journal-title":"Gut Liver"},{"key":"10.1016\/j.biopha.2025.118185_bib19","first-page":"S1","article-title":"R. Yadlapati, Updates in the management of erosive esophagitis","volume":"72","author":"Pandolfino","year":"2023","journal-title":"J. Fam. Pr."},{"key":"10.1016\/j.biopha.2025.118185_bib20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3748\/wjg.v30.i9.1108","article-title":"Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China","volume":"30","author":"Yang","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118185_bib21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/jgh.16017","article-title":"A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis","volume":"37","author":"Simadibrata","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118185_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221122623","article-title":"The role of vonoprazan in patients with erosive esophagitis","volume":"15","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118185_bib23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1358\/dot.2020.56.11.3202811","article-title":"Tegoprazan to treat gastroesophageal reflux disease","volume":"56","author":"Mermelstein","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.biopha.2025.118185_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MED.0000000000000858","article-title":"Potassium-competitive acid blockers and acid-related disorders","volume":"31","author":"Huang","year":"2024","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.biopha.2025.118185_bib25","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis","volume":"28","author":"Lee","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118185_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jgh.16471","article-title":"The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study","volume":"39","author":"Zhuang","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118185_bib27","doi-asserted-by":"crossref","first-page":"14589","DOI":"10.3390\/ijms241914589","article-title":"Anti-inflammatory effects of tegoprazan in lipopolysaccharide-stimulated bone-marrow-derived macrophages","volume":"24","author":"Han","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118185_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114290","article-title":"Revaprazan prevented indomethacin-induced intestinal damages by enhancing tight junction related mechanisms","volume":"182","author":"Han","year":"2020","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12793\/tcp.2023.31.e3","article-title":"Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation","volume":"31","author":"Yang","year":"2023","journal-title":"Transl. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22459","article-title":"Interactions between cyazofamid and human drug transporters","volume":"34","author":"Song","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.biopha.2025.118185_bib31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/pharmaceutics13091496","article-title":"Effect of lactic acid bacteria on the pharmacokinetics and metabolism of ginsenosides in mice","volume":"13","author":"Jeon","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118185_bib32","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/biom12121896","article-title":"Concomitant administration of red ginseng extract with lactic acid bacteria increases the plasma concentration of deglycosylated ginsenosides in healthy uuman subjects","volume":"12","author":"Jeon","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118185_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394Cq method method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.biopha.2025.118185_bib34","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4049\/jimmunol.1402300","article-title":"Porcine \u03b2-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis","volume":"194","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2025.118185_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s13318-012-0099-4","article-title":"Differential effect of oxidative stress on intestinal apparent permeability of drugs transported by paracellular and transcellular route","volume":"37","author":"Dixit","year":"2012","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib36","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1021\/acs.molpharmaceut.9b00733","article-title":"The permeation of acamprosate is predominantly caused by paracellular diffusion across Caco-2 cell monolayers: A paracellular modeling approach","volume":"16","author":"Antonescu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib37","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","article-title":"Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability","volume":"14","author":"Gradauer","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12793\/tcp.2017.25.2.74","article-title":"Parameter estimation for sigmoid Emax models in exposure-response relationship","volume":"25","author":"Choe","year":"2017","journal-title":"Transl. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-020-00549-7","article-title":"Population pharmacodynamic modeling using the sigmoid Emax model: influence of inter-individual variability on the steepness of the concentration-effect relationship. a simulation study","volume":"23","author":"Proost","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2025.118185_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/00365521.2023.2255710","article-title":"The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway","volume":"59","author":"Fossmark","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118185_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109200","article-title":"effects of Bee pollen extract on the Caco-2 intestinal barrier dysfunctions induced by dextran sulfate sodium","volume":"117","author":"Li","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib43","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.3390\/ijms21082726","article-title":"Dextran sodium sulfate-induced impairment of protein trafficking and alterations in membrane composition in intestinal Caco-2 cell line","volume":"21","author":"Toutounji","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118185_bib44","first-page":"1357","article-title":"In vitro effects of dextran sulfate sodium on a Caco-2 cell line and plausible mechanisms for dextran sulfate sodium-induced colitis","volume":"16","author":"Araki","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118185_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/ijms21030993","article-title":"Contributions of myosin light chain kinase to regulation of epithelial paracellular permeability and mucosal homeostasis","volume":"21","author":"He","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118185_bib46","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1007\/s00405-024-08877-6","article-title":"Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial","volume":"281","author":"Kim","year":"2024","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.biopha.2025.118185_bib47","first-page":"4218","article-title":"Epithelial-derived gasdermin D mediates nonlytic IL-1\u03b2 release during experimental colitis","volume":"130","author":"Bulek","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118185_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178662","article-title":"Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors","volume":"14","author":"Dai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118185_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1218477","article-title":"\u03b2-sitosterol alleviates dextran sulfate sodium-induced experimental colitis via inhibition of NLRP3\/Caspase-1\/GSDMD-mediated pyroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41417-024-00796-2","article-title":"Gut microbiota-mediated activation of GSDMD ignites colorectal tumorigenesis","volume":"31","author":"Chen","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118185_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2022.10.022","article-title":"Potassium-competitive acid blocker suppression of gastric acid in erosive esophagitis: Is stronger and longer better?","volume":"164","author":"Katzka","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118185_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: A randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118185_bib55","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/apt.16131","article-title":"Pharmacodynamics and pharmacokinetics of DWP14012 (Fexuprazan) in healthy subjects with different ethnicities","volume":"52","author":"Hwang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118185_bib56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/pharmaceutics13060813","article-title":"Development of physiologically based pharmacokinetic model for orally administered fexuprazan in humans","volume":"13","author":"Jeong","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118185_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/ph15060709","article-title":"Model-based prediction of acid suppression and proposal of a new dosing regimen of fexuprazan in humans","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118185_bib58","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41401-019-0353-2","article-title":"Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous\/oral administration to rats, dogs and humans","volume":"41","author":"Kong","year":"2020","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:47:19Z","timestamp":1758124039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":58,"alternative-id":["S0753332225003798"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118185","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118185"}}